Gene therapy for infantile malignant osteopetrosis: review of pre-clinical research and proof-of-concept for phenotypic reversal
Open Access
- 1 March 2021
- journal article
- review article
- Published by Elsevier in Molecular Therapy - Methods & Clinical Development
- Vol. 20, 389-397
Abstract
No abstract availableKeywords
This publication has 80 references indexed in Scilit:
- Efficient, Long Term Production of Monocyte-Derived Macrophages from Human Pluripotent Stem Cells under Partly-Defined and Fully-Defined ConditionsPLOS ONE, 2013
- Mouse Transplant Models for Evaluating the Oncogenic Risk of a Self-Inactivating XSCID Lentiviral VectorPLOS ONE, 2013
- Retroviral Gene Therapy for X-linked Chronic Granulomatous Disease: Results From Phase I/II TrialMolecular Therapy, 2011
- Biochemical Correction of X-CGD by a Novel Chimeric Promoter Regulating High Levels of Transgene Expression in Myeloid CellsMolecular Therapy, 2011
- Stem-Cell Gene Therapy for the Wiskott–Aldrich SyndromeNew England Journal of Medicine, 2010
- A self-inactivating lentiviral vector for SCID-X1 gene therapy that does not activate LMO2 expression in human T cellsBlood, 2010
- OsteopetrosisOrphanet Journal of Rare Diseases, 2009
- Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patientsJournal of Clinical Investigation, 2008
- Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1Journal of Clinical Investigation, 2008
- A Serious Adverse Event after Successful Gene Therapy for X-Linked Severe Combined ImmunodeficiencyNew England Journal of Medicine, 2003